Daniel leads our global corporate development team, which includes mergers & acquisitions, licensing, collaborations, alliance management, and integration. Under his leadership, the team evaluates external opportunities and executes business development transactions. These deals drive growth and accelerate Organon’s strategy by building the company’s pipeline and portfolio.
Prior to joining Organon, Daniel served as Executive Vice President, Corporate Development at Biogen. Previously, he held a number of positions of increasing responsibility at Pfizer, including VP, Head of BD for Worldwide Research & Development, and VP, Head of BD for Pfizer Vaccines, Oncology and Consumer Healthcare. Throughout his career, Daniel and his teams have executed M&A and collaboration deals totaling over $80B in potential value. Most importantly, these transactions have brought new drugs, gene therapies, vaccines, devices, and technologies closer to the patients who need them. Earlier in his career, Daniel held roles in healthcare and life sciences strategy consulting.
Daniel has a B.S. in biology from Duke University and an M.B.A. from the Wharton School of the University of Pennsylvania. Currently, he serves as Director on the board of Cartesian Growth Corp II and previously served on the board of Cartesian Growth Corp, which combined with Tiedemann Group and Alvarium Investments.
What is Daniel Karp's net worth?
The estimated net worth of Daniel Karp is at least $332.75 thousand as of May 6th, 2025. Karp owns 46,669 shares of Organon & Co. stock worth more than $332,750 as of December 5th. This net worth approximation does not reflect any other assets that Karp may own. Learn More about Daniel Karp's net worth.
How old is Daniel Karp?
Karp is currently 46 years old. There are 6 older executives and no younger executives at Organon & Co.. The oldest executive at Organon & Co. is Mr. Kevin Ali, CEO & Director, who is 64 years old. Learn More on Daniel Karp's age.
How do I contact Daniel Karp?
Has Daniel Karp been buying or selling shares of Organon & Co.?
Daniel Karp has not been actively trading shares of Organon & Co. during the past quarter. Most recently, on Tuesday, May 6th, Daniel Karp bought 3,500 shares of Organon & Co. stock. The stock was acquired at an average cost of $8.24 per share, with a total value of $28,840.00. Following the completion of the transaction, the vice president now directly owns 46,669 shares of the company's stock, valued at $384,552.56. Learn More on Daniel Karp's trading history.
Who are Organon & Co.'s active insiders?
Are insiders buying or selling shares of Organon & Co.?
During the last year, Organon & Co. insiders bought shares 6 times. They purchased a total of 102,345 shares worth more than $902,430.45. The most recent insider tranaction occured on May, 6th when insider Kirke Weaver bought 8,045 shares worth more than $74,094.45. Insiders at Organon & Co. own 2.0% of the company.
Learn More about insider trades at Organon & Co.. Information on this page was last updated on 5/6/2025.
